Evaluation of Drug Interaction, Safety, and Tolerability of UIC202601 and UIC202602 in Healthy Adults Aged 19 to 54

What this Trial Is About

This research aims to evaluate the pharmacokinetic interaction, safety, and tolerability of two investigational drugs, UIC202601 and UIC202602, in healthy adult volunteers aged 19 to 54 years. The study is a randomized, open-label, two-arm, two-period, multiple-dose trial designed to understand how these drugs interact when taken alone or in combination. Participants receive UIC202601 alone, UIC202602 alone, or both drugs together at a dose of 1 or 2 tablets per day respectively, over 7 days. The study uses a crossover model where participants receive each treatment in separate periods, allowing researchers to compare drug effects within the same individual. During the trial, participants undergo thorough medical evaluations including blood tests, physical exams, and ECGs to monitor safety and drug levels. The primary measures are the drug concentrations in the blood over 24 hours after steady state dosing. The total study duration includes screening, treatment periods, and follow-up to assess tolerability and pharmacokinetics until September 2026.

A Randomized, Open-label, Two-arm, Two-period, Multiple-dose, Study to Evaluate Pharmacokinetic Drug-drug Interaction, Safety and Tolerability of UIC202601 and UIC202602 in Healthy Volunteers